Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: Resistance to AR

AIDS Research and Human Retroviruses

Volumn 23, Issue 2, 2007, Pages 335-340

  Deshpande, Alaka ^a   Jauvin, Valérie ^b   Magnin, Noel ^b   Pinson, Patricia ^b   Faure, Muriel ^b   Masquelier, Bernard ^b   Aurillac Lavignolle, Valérie ^c   Fleury, Hervé J ^b,d  

^a SIR J J GROUP OF HOSPITALS   (India)

^b University Victor Segalen   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TREATMENT FAILURE;

EID: 33947252946     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0183     Document Type: Article

References (13)

1. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, and Shafer RW: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2(4):e112.
2. Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vezinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, and Vandamme AM: Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006;50(2): 694-701.
3. van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, Macrae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, and Boucher CA: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006;41(3):352-360.
4. Deshpande A, Pinson P, Deshmukh R, Faure M, Jauvin V, and Fleury HJ: Molecular characterization of HIV-1 isolates from untreated patients of Mumbai (Bombay), India; XV AIDS Conference, Bangkok, Thailand, 11-16 July 2004, Abstract WePeB5759.
5. Deshpande A, Recordon-Pinson P, Deshmukh R, Faure M, Jauvin V, Garrigue I, Lafon ME, and Fleury HJ: Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses 2004;20(9): 1032-1035.
6. Fleury HJ, Toni T, Lan NT, Hung PV, Deshpande A, Recordon-Pinson P, Boucher S, Lazaro E, Jauvin V, Lavignolle-Aurillac V, Lebel-Binay S, Cheret A, and Masquelier B: Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: Comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses 2006;22(4):357-366.
7. Plantier JC, Dachraoui R, Lemee V, Gueudin M, Borsa-Lebas F, Caron F, and Simon F: HIV-1 resistance genotyping on dried serum spots. AIDS 2005;19(4):391-397.
8. Merel P, Pellegrin I, Garrigue I, Caumont A, Schrive MH, Birac V, Bonot P, and Fleury H: Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA analysis system to conventional gel based systems for HIV drug resistance analysis. J Virol Methods 2001;98(1):9-16.
9. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, and Shafer RW: Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003;17(6):791-799.
10. Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T, and Wainberg MA: Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses 2003;19(9):743-753.
11. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, and Wainberg MA: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17(1):F1-5.
12. Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R, von Lieven A, Israelski D, and Katzenstein DA: HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2002;18(18):1407-1413.
13. Montes B, Vergne L, Peelers M, Reynes J, Delaporte E, and Segondy M: Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004;35(4):329-336.